Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT Account Payables

Amounts the company owes suppliers for goods and services received.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables falls 33.8% from a year ago

Account payables stood at $4.09M at the end of Q1 FY2026, down 33.8% from a year earlier and down 3.4% from the prior quarter. Over 3 fiscal years it compounded at -17.2% a year.

Context

  • Account payables amounted to 1.7% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
  • Account payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether account payables keeps falling in the next quarterly balance sheet after a -33.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.09M-3.4% QoQ
Last fiscal yearDec 2025
$4.24M-41.1% YoY
Year agoMar 2025
$6.18M-33.8% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.8%——
1 year-41.1%——
3-year CAGR-17.2%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
4.24M USD
Year-over-year change
-41.1%
4-year CAGR
-19.4%

Account Payables vs competitors

How ARCT compares with its peers on the latest reported figures

  • Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -33.8% is the 5th highest of 11, against a peer median of -39.8%.
  • Account payables amounts to 1.7% of total assets for ARCT, versus a peer median of 1.0%.
ARCT Competitors
Account Payables for ARCT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VALNValneva SEMar 2026€21.83M EUR-21.6%-14.5%5.9%
NVAXNovavax, Inc.Mar 2026$16.1M USD-52.9%-51.6%1.5%
SLNSilence Therapeutics plcMar 2026$10.37M USD-44.9%+11.4%9.0%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$9.45M USD+27.9%+71.8%3.5%
VIRVir Biotechnology, Inc.Mar 2026$5.45M USD+46.2%+15.1%0.5%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$4.09M USD-33.8%-17.2%1.7%
INOInovio Pharmaceuticals, Inc.Mar 2026$1.99M USD-64.0%-50.1%4.0%
ABUSArbutus Biopharma CorporationMar 2026$1.46M USD-34.7%-30.7%0.5%
BNTCBenitec Biopharma Inc.Mar 2026$635K USD+46.7%-21.9%0.3%
PRQRProQR Therapeutics N.V.Mar 2026€189.2K EUR-57.7%-8.7%0.2%
RCKTRocket Pharmaceuticals, Inc.Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding ARCT) —-39.8%-14.5%1.0%

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents370.49M391.88M292.01M237.03M230.91M
Short-term Investments00000
Net Receivables3.37M2.76M32.06M3.97M5.56M
Inventory00000
Other Current Assets08.69M55M64.98M4.97M
Total Current Assets378.96M403.33M386.59M305.98M241.45M
Property, Plant & Equipment (Net)11.26M44.96M40.93M36.21M27.82M
Goodwill00000
Intangible Assets00000
Long-term Investments515K01.89M01.89M
Tax Assets00000
Other Non-current Assets2.08M2.09M01.89M0
Total Non-current Assets13.85M47.05M42.81M38.09M29.7M
Total Assets392.81M450.39M429.4M344.07M271.15M
Account Payables10.06M7.45M5.28M7.19M4.24M
Short-term Debt22.47M60.66M000
Tax Payables01.3M641K00
Deferred Revenue43.48M36.12M47.34M21.94M8.25M
Other Current Liabilities3.58M4.04M18.5M13.31M6.95M
Total Current Liabilities99.54M126.98M81.99M65.49M36.38M
Long-term Debt40.63M0000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)020.07M42.5M12.6M0
Other Non-current Liabilities19.93M2.8M497K00
Total Non-current Liabilities65.07M53.09M68.9M37.6M20.78M
Total Liabilities164.6M180.08M150.89M103.09M57.16M
Common Stock26K27K27K27K28K
Retained Earnings(347.49M)(338.14M)(367.87M)(448.81M)(514.59M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity228.21M270.31M278.51M240.98M213.99M
Total Debt69.15M94.76M30.22M28.55M25M
Net Debt(301.35M)(297.13M)(261.79M)(208.48M)(205.91M)

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.